Table 6.

Efficacy of lanreotide Autogel^® compared with octreotide LAR and lanreotide SR in acromegaly

Reference	Duration (months)	Patient no ITT/PPP	Octreotide LAR dose	Lanreotide Autogel dose	Normal GH oLAR	Normal GH lanreotide Autogel	Normal IGF-I oLAR	Normal IGF-I lanreotide Autogel
Alexopoulou 2004	6	25/25	20–40 mg/4 w	60/90/120 mg	64%	48%	52%	52%
Ronchi 2007	9	23/21	10–30 mg/4 w	60/90/120 mg	40%	56%	35%	39%
Andries 2008	12	12/10	10–30 mg/4 w	Fixed dose 60/90/120 mg	50%	50%a	50%	60%

^anormal GH concentration <0.38 μg/L.

Abbreviations: ITT, intention-to-treat; PPP, patients per protocol; oLAR, octreotide LAR.